In this paper, the study of human transfer factor is reported. We established a negative pressure dialysis method instead of ordinary dialysis for treatment of the crude leukocyte extract. Dialysate is rapidly obtained in only 5 h so that a large volume of preparation is easier to handle and the chance of contamination avoided. When human TF was incubated with human cord blood T-lymphocytes and pig lymphocytes, a very high biological activity on SRBC rosette enhancement and an increase in electrophoresis rate appeared. It suggests that these assays may be used as in vitro method of evaluation of TF activity. In our clinic, TF has been in clinical trials for 5 years and has now been administered to a large number of patients with a variety of diseases, in which cell-mediated immune responses have been compromised. We observe that TF has served an efficient immunopotentiating or immunomodulation agent.
